Silexion Therapeutics Corp Sustainability Reports
A clinical-stage biotechnology company that focuses on discovering and developing RNA interference (RNAi)-based treatments for KRAS-driven cancers, particularly locally advanced pancreatic cancer.
Sector: Manufacturing
Country: Israel
Exchange: Nasdaq
1 reports from 2024 to 2024
Company Profile
A clinical-stage biotechnology company that focuses on discovering and developing RNA interference (RNAi)-based treatments for KRAS-driven cancers, particularly locally advanced pancreatic cancer.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years